Legal & General Group PLC Verona Pharma PLC Transaction History

Legal & General Group PLC

$368 Billion
Q4 2024

A detailed history of Legal & General Group PLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Legal & General Group PLC holds 143,216 shares of VRNA stock, worth $9.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

143,216

Previous 378,004 62.11%

Holding current value

$9.1 Million

Previous $10.9 Million 38.85%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$28.71 - $47.02 $6.74 Million - $11 Million	-234,788 Reduced 62.11%	143,216 $6.65 Million
Q3 2024 Feb 28, 2025	BUY	$15.46 - $30.16 $3.63 Million - $7.08 Million	234,788 Added 163.94%	378,004 $10.9 Million
Q3 2024 Nov 14, 2024	SELL	$15.46 - $30.16 $95,913 - $187,112	-6,204 Reduced 1.61%	378,004 $10.9 Million
Q2 2024 Aug 14, 2024	BUY	$11.48 - $17.02 $3.5 Million - $5.18 Million	304,635 Added 382.84%	384,208 $5.56 Million
Q1 2024 May 14, 2024	SELL	$15.3 - $20.24 $14,397 - $19,045	-941 Reduced 1.17%	79,573 $1.28 Million
Q4 2023 Feb 15, 2024	BUY	$11.94 - $20.47 $151,208 - $259,232	12,664 Added 18.66%	80,514 $1.6 Million
Q3 2023 Nov 14, 2023	BUY	$16.3 - $22.09 $111,655 - $151,316	6,850 Added 11.23%	67,850 $1.11 Million
Q2 2023 Aug 14, 2023	BUY	$19.41 - $23.43 $710,871 - $858,100	36,624 Added 150.25%	61,000 $1.29 Million
Q1 2023 May 15, 2023	SELL	$18.06 - $25.27 $5,002 - $6,999	-277 Reduced 1.12%	24,376 $489,000
Q4 2022 Feb 14, 2023	BUY	$9.84 - $26.13 $242,585 - $644,182	24,653 New	24,653 $644,000

Others Institutions Holding VRNA

# of Institutions

219

Shares Held

70.5M

Call Options Held

1.4M

Put Options Held

299K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $3.87B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Verona Pharma PLC Transaction History